Isolation of monoclonal immunoglobulin from plasma of patients with multople myeloma using affinity chromatography

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F02%3A00006850" target="_blank" >RIV/00216224:14110/02:00006850 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Isolation of monoclonal immunoglobulin from plasma of patients with multople myeloma using affinity chromatography

Popis výsledku v původním jazyce

Multiple myeloma is characterized by the proliferation of a malignant plasma cell clone and accounts for approximately 10% of hematological malignancies. High-dose chemotherapy with autologous transplantation has improved the survival of patients with myeloma, hovewer, relapse is inevitable (1,2). Recent research has targeted the minimal residual disease. One of the therapeutical options is this setting is immunotherapy using specific tumor antigen as a vaccine. The idiotype of myeloma immunoglobulin (Id protein) is specifically expressed by malignant cells and can be used as a tumor antigen with the aim to induce cytotoxic T-lymphocyte response against myeloma cells (3,4,5,6). For purification of Id protein from plasma of relapsed IgG myeloma patientswho were before reinduction treatment, plasma was precipitated with a saturated solution of ammonium sulfate. After precipitation and dialysis in saline at pH 7.3 to remove ammonium sulfate, the Id protein was separated on protein G immo

Název v anglickém jazyce

Isolation of monoclonal immunoglobulin from plasma of patients with multople myeloma using affinity chromatography

Popis výsledku anglicky

Multiple myeloma is characterized by the proliferation of a malignant plasma cell clone and accounts for approximately 10% of hematological malignancies. High-dose chemotherapy with autologous transplantation has improved the survival of patients with myeloma, hovewer, relapse is inevitable (1,2). Recent research has targeted the minimal residual disease. One of the therapeutical options is this setting is immunotherapy using specific tumor antigen as a vaccine. The idiotype of myeloma immunoglobulin (Id protein) is specifically expressed by malignant cells and can be used as a tumor antigen with the aim to induce cytotoxic T-lymphocyte response against myeloma cells (3,4,5,6). For purification of Id protein from plasma of relapsed IgG myeloma patientswho were before reinduction treatment, plasma was precipitated with a saturated solution of ammonium sulfate. After precipitation and dialysis in saline at pH 7.3 to remove ammonium sulfate, the Id protein was separated on protein G immo

Druh

D - Stať ve sborníku

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NC6763" target="_blank" >NC6763: Využití monoklonálního imunoglobulinu k přípravě protinádorové vakcíny u nemocných s mnohočetným myelomem</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2002

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

Zborník XVII.Biochemický zjazd

ISBN

nepřiděleno

ISSN

—

e-ISSN

—

Počet stran výsledku

1

Strana od-do

223

Název nakladatele

VEDA, vydavatelstvo SAV, Bratislava

Místo vydání

Bratislava, SR

Místo konání akce

10.-13.9.2002 Stará lesná

Datum konání akce

1. 1. 2002

Typ akce podle státní příslušnosti

EUR - Evropská akce

Kód UT WoS článku

—